Ackman's Pershing Square Boosts Stake in Valeant to 9.9%
November 23 2015 - 5:20PM
Dow Jones News
William Ackman's Pershing Square Capital Management LP disclosed
a boosted 9.9% stake in Valeant Pharmaceuticals International Inc.,
a move that comes after the hedge-fund manager said he had taken
advantage of the beaten-down market for the stock to build up his
position.
Mr. Ackman has vigorously defended his multibillion-dollar
investment in the pharmaceutical company, which has come under
siege over its accounting and sales tactics.
Pershing Square's latest acquisitions are primarily shares
underlying call options. The fund bought 2.1 million common shares
and call options tied to 12.5 million shares for a total of about
$475 million. It also sold options, garnering $169 million.
The fund now beneficially owns 34.1 million shares, which
include 21.6 million common shares and 12.5 million shares
underlying options.
Mr. Ackman told CNBC in late October that he had bought the 2
million shares, a vote of confidence in the company as its shares
declined.
Valeant shares rose 3% to $89.99 after hours. The stock traded
above $260 in early August.
Write to Lauren Pollock at lauren.pollock@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
November 23, 2015 18:05 ET (23:05 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Apr 2024 to May 2024
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Bausch Health Cos (New York Stock Exchange): 0 recent articles
More Valeant Pharmaceuticals International News Articles